Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Basel Medical GroupBMGL -24.94%17 EBITDA Margin % is 31.56% as of Dec. 2025, which is 4% above its 10-year median of 30.49. GuruFocus rates BMGL with a GF Score™ of 17/100. The stock has 3 warning signs investors should review. Among 665 Healthcare Providers & Services companies, Basel Medical Group ranks worse than 88.27% on this metric.
Basel Medical Group (NAS:BMGL) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Basel Medical Group EBITDA Margin % Related Terms
Basel Medical Group EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Basel Medical Group's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BMGL vs AMS, HLYK, BICX: EBITDA Margin % Comparison
For the Medical Care Facilities subindustry, Basel Medical Group's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Basel Medical Group EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Basel Medical Group's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Basel Medical Group's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Basel Medical Group (BMGL) has a EBITDA Margin % of 31.56% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Basel Medical Group and its competitors. This is near median its historical median of 30.49. According to the industry distribution chart, Basel Medical Group ranks #587 out of 665 companies in the Healthcare Providers & Services industry, placing it in the top 88.3%.
Is Basel Medical Group's EBITDA Margin % too high?
Basel Medical Group's current EBITDA Margin % of 31.56% is near median its 10-year median of 30.49. The Healthcare Providers & Services industry median EBITDA Margin % is 10.24. Basel Medical Group's value of 31.56% is 208.2% above this industry median. Based on the distribution chart, Basel Medical Group ranks #587 out of 665 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Basel Medical Group has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Basel Medical Group's EBITDA Margin % compare to AMS and HLYK?
According to the Healthcare Providers & Services industry distribution chart, Basel Medical Group ranks #587 out of 665 companies for EBITDA Margin %. This places Basel Medical Group in the lower half of its industry. The industry median EBITDA Margin % is 10.24. Basel Medical Group's value of 31.56% is 208.2% above this benchmark. While the company's 10-year median is 30.49 vs. the industry median of 10.24, Basel Medical Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.24, based on 665 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Basel Medical Group's current EBITDA Margin % of 31.56% is 208.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Basel Medical Group and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Basel Medical Group's current EBITDA Margin % is 31.56%, which is near median its own 10-year median of 30.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Basel Medical Group stock overvalued right now?
Basel Medical Group (BMGL) has a current EBITDA Margin % of 31.56%. The current EBITDA Margin % is 31.56%, which is near median its 10-year median of 30.49 and 208.2% above the Healthcare Providers & Services industry median of 10.24. Basel Medical Group's overall GF Score™ is 17/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Basel Medical Group (BMGL), the current EBITDA Margin % is 31.56% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Basel Medical Group Ltd provides general and subspecialized orthopedic, trauma and sports medicine services such as knee/hip replacements, sports medicine/surgery, spine surgery, foot/ankle surgery and minimally invasive orthopedic procedures, as well as neurosurgical treatments. The services provided by clinics include, but are not limited to, consultation, medical diagnosis and medical or surgical treatments for orthopedic, trauma, sports medicine, general practice, health screening, mental health, women's health and neurosurgical conditions and clinics are equipped with the facilities needed to perform a variety of procedures on site and minor surgical services. Key revenue is generated from Singapore.
17GF Score
Get the complete analysis for BMGL
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BMGL has been successfully added to your 
